MREO
Mereo BioPharma Group plc (MREO) Business Model Analysis (2026)
Overall Score
Revenue Model
No meaningful revenue base is reflected in the latest TTM metrics, so the business model remains pre-commercial or highly limited in current monetization.
Valuation is still anchored more to balance-sheet value than sales, with price-to-sales reported at 0 and enterprise value at just 13.6M.
Profitability
TTM margins remain at 0 across gross, operating, EBITDA, pretax, and net profit, indicating no current operating profitability.
Returns are still deeply negative, with ROA at -80.9%, ROE at -74.8%, and ROIC at -111.4%.
Cash Flow
Operating cash flow and free cash flow remain negative, with FCF per share at -0.1577 and FCF yield at -59.43%.
Cash conversion remains poor despite a high current ratio, as operating cash flow ratio is negative and cash flow coverage metrics are not supportive.
Balance Sheet
Liquidity remains strong, with a current ratio of 5.88 and cash ratio of 5.31.
Leverage is still low, with debt-to-equity at 0.036 and debt-to-assets at 0.030, supporting financial flexibility.
Capital Efficiency
Capital efficiency remains weak, with return on invested capital at -111.4% and return on capital employed at -117.7%.
Asset turnover is effectively zero, showing the company is not yet generating meaningful revenue from its asset base.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Mereo BioPharma Group plc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

